Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23317823 | 1.00 | NTRK1 (0.62) | NTRK1JAK2 | |
| SCHEMBL21911085 | 0.87 | NTRK1 (0.70) | NTRK1JAK2 | |
| SCHEMBL22849675 | 0.85 | NTRK1 (0.48) | NTRK1JAK2 | |
| SCHEMBL23317826 | 0.85 | NTRK1 (0.48) | NTRK1JAK2 | |
| SCHEMBL23732305 | 0.85 | NTRK1 (0.67) | NTRK1JAK2 | |
| SCHEMBL24833960 | 0.84 | NTRK1 (0.45) | NTRK1JAK2 | |
| SCHEMBL22849828 | 0.81 | NTRK1 (0.47) | NTRK1JAK2 | |
| SCHEMBL23317821 | 0.81 | NTRK1 (0.47) | NTRK1JAK2 | |
| SCHEMBL21912034 | 0.78 | NTRK1 (0.66) | NTRK1JAK2 | |
| SCHEMBL2694390 | 0.77 | NTRK1 (1.00) | NTRK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11464780-B2 | Pyrazolopyrimidine derivative and use thereof | SIMCERE PHARMACEUTICAL CO. LTD. (CN) | 2022-10-11 | — | — | US | disclosed |
| EP-4023648-A1 | CRYSTAL OF CARCINOGENIC FUSED KINASE INHIBITOR AND APPLICATIONS THEREOF | Simcere Pharmaceutical Co. Ltd. (CN) | 2022-07-06 | — | — | EP | disclosed |
| WO-2021037156-A1 | CRYSTAL OF CARCINOGENIC FUSED KINASE INHIBITOR AND APPLICATIONS THEREOF | 南京明德新药研发有限公司 | 2021-03-04 | — | — | WO | disclosed |
| US-20200405725-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE AND USE THEREOF | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200405725-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE AND USE THEREOF | TPMT, VHL, GOT2 | NTRK1 3063/4885JAK2 34/4885 |
| US-11464780-B2 | Pyrazolopyrimidine derivative and use thereof | TPMT, VHL, GOT2 | NTRK1 3063/4885JAK2 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.